Protection afforded by a selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, against drug-induced liver injury.

本研究旨在评价选择性血栓素A2合成酶抑制剂ozagrel对对乙酰氨基酚诱导的小鼠肝损伤的作用。血清ALT显示，奥扎格雷尔能有效减轻对乙酰氨基酚引起的肝损伤，并呈剂量和时间依赖性减弱肝肿瘤坏死和核DNA断裂。此外，对乙酰氨基酚肝损伤后延迟给药ozagrel比n -乙酰半胱氨酸更有效。结果表明，奥扎格雷尔是预防对乙酰氨基酚引起的肝损伤的一种有前景的候选药物。

This study was conducted to evaluate the effects of ozagrel, a selective thromboxane A2 synthase inhibitor, against acetaminophen-induced hepatic injury in mouse. Ozagrel effectively attenuated the acetaminophen-induced hepatic damage as indicated by the serum ALT, and oncotic necrosis and nuclear DNA fragmentation in liver in dose- and time-dependent manner. In addition, delayed administration of the ozagrel was more effective than N-acetylcysteine after the acetaminophen liver injury. The results suggest that ozagrel is a promising drug candidate for preventing acetaminophen-induced hepatic injury.